Pyridoxamine reduces methylglyoxal and markers of glycation and endothelial dysfunction, but does not improve insulin sensitivity or vascular function in abdominally obese individuals: a randomized double-blind placebo-controlled trial.
Mathias D G Van den EyndeA J H M HoubenJ L J M ScheijenA M A LinkensP M NiessenN SimonsNordin M J HanssenY H A M KustersS J M P EussenT MiyataCoen D A StehouwerC G SchalkwijkPublished in: Diabetes, obesity & metabolism (2023)
This study shows that PM is metabolically active and reduces MGO, AGEs, sVCAM-1, and sICAM-1, but does not affect insulin sensitivity and vascular function in abdominally obese individuals. The reduction of the adhesion markers is promising since these are important in the pathogenesis of endothelial damage and atherosclerosis. This study was registered at the ClinicalTrials.gov database with identifier number NCT02954588. This article is protected by copyright. All rights reserved.